Summary: MAPS “must raise about $7.5m by September as part of what it calls the MAPS Capstone Challenge,” explains Marc Gunther in his recent Medium article. “The funds are needed to unlock a challenge grant of $10m and to complete a final round of clinical trials.” Gunther, highlighting the compelling results from clinical trials of MDMA-assisted psychotherapy for PTSD, explains the pivotal significance that FDA approval will have on the field of psychedelic medicine and mental healthcare, potentially bringing “relief to millions of people suffering from PTSD.”
Originally appearing here.